Kiniksa Pharmaceuticals Interna (KNSA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kiniksa Pharmaceuticals Interna

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$89.20+16.22(0.22%)Pre-market

Market Cap

$7.21B

P/E

65.8x

P/S

7.6x

P/B

10.2x

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

How this company scores

ExcellentMetricSide Score: 85/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability23/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 65.8x5y range 3.8x – 424.2x

Currently near its 12-quarter median.

P/S · 7.6x5y range 3.2x – 21.4x

Currently above its 20-quarter median.

P/B · 10.2x5y range 1.9x – 10.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Red Flag

Shares outstanding increased 8.1% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $7.21B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $945.96M
Q. Revenue: $285.97M
TTM EBITDA: $130.47M
TTM Op. Income: $130.47M
Q. Op. Income: $54.24M
TTM Net Income: $109.57M
Q. Net Income: $47.34M
EPS: $0.61
Shares Out.: $78.19M

$945.96M in TTM revenue grew 58.2% YoY, reaching $285.97M last quarter. TTM EBITDA of $130.47M and TTM operating income of $130.47M show growth is flowing through to the bottom line. TTM net income of $109.57M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 90.3%
EBITDA Margin: 19.0%
Op. Margin: 19.0%
Net Margin: 16.6%

Op. margin of 19.0% is up 5.7% YoY — cost efficiency is improving. Net margin at 16.6% and gross margin of 90.3% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 43% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 65.8x
P/S Ratio: 7.6x
P/B Ratio: 10.2x

At 65.8x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 7.6x and P/B of 10.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 6 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $983.24M
Cash: $81.66M
Long-Term Debt: N/A
Book Value: $710.19M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $47.55M
TTM Free Cash Flow: $197.20M
FCF Margin: 20.8%
FCF / Net Income: 1.8

TTM FCF of $197.20M on $47.55M in operating cash flow. The FCF / Net Income ratio of 1.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.